Orchid Cellmark's forensic DNA testing services aid in exoneration of NJ man wrongfully convicted of brutal rape and murder

Pro Bono Laboratory Services Supplied to the Innocence Project Help in Freeing Another Wrongfully Convicted Individual After Years of Incarceration

Princeton, NJ - July 10, 2007 Orchid Cellmark Inc. (Nasdaq: ORCH), a leading worldwide provider of identity DNA testing services, today announced that DNA analysis at one of the company’s forensic laboratories supported the work of the Innocence Project in securing the full exoneration of Byron Halsey, wrongfully convicted of the brutal sexual assault and murders of two young children in New Jersey 22 years ago. Mr. Halsey, who narrowly escaped the death penalty when convicted in 1988, was exonerated based on DNA evidence that proves his innocence and indicates that a man who helped convict Halsey is the actual perpetrator. The DNA analysis was part of a package of pro bono services supplied by Orchid Cellmark to the Innocence Project in New York as a public service.

"It is a privilege for Orchid Cellmark to have the opportunity to contribute our DNA analysis expertise to the untiring work of the Innocence Project in securing justice for wrongfully convicted individuals throughout the nation," said Mark Stolorow, Executive Director of Forensic Science at Orchid Cellmark, who earlier in his career was involved in the first case in the U.S. to use DNA to reverse a conviction. "DNA analysis has been central to many of these cases, and as a pioneer in forensic DNA we are reminded daily of the power of this technology to serve the cause of justice by exonerating the innocent and convicting the guilty. We are particularly pleased to have helped in this case in our home state of New Jersey, exonerating an innocent man wrongfully convicted of horrific crimes against the children he loved."

Halsey’s conviction was overturned in May after DNA testing on several key pieces of evidence used to convict Halsey actually indicated the guilt of another man, Cliff Hall, who is already in prison for several other sex crimes in New Jersey and who testified against Halsey during his trial. The District Attorney’s office consented to the DNA testing, which was conducted at Orchid Cellmark and in state laboratories. Hall has now been charged with the crimes for which Halsey was wrongfully convicted. As in Halsey’s case, DNA in more than 37% of exoneration cases nationwide also helped identify the true perpetrator of the crimes, according to the Innocence Project..

Last year, Orchid Cellmark worked with the Innocence Project in securing the exonerations of a number of individuals who had been wrongfully imprisoned for decades. Orchid Cellmark has also provided forensic DNA analyses in such high profile cases as the OJ Simpson investigation, the JonBenet Ramsey murder, the Gary Ridgway "Green River" serial killer case, and the Unabomber investigation, which eventually resulted in the conviction of Ted Kaczynski.

Orchid Cellmark is one of the oldest and most experienced providers of forensic DNA testing services and it has conducted DNA testing for the FBI and for criminal justice agencies in all 50 U.S. states and hundreds of municipalities, as well as for many law enforcement agencies in the U.K. Orchid Cellmark’s U.S-based forensic laboratories have received the prestigious accreditation of the American Society of Crime Laboratory Directors/Laboratory Accreditation Board (ASCLD/LAB). Orchid Cellmark’s U.S.-based laboratories are also accredited by the National Forensic Science Technology Center.

About Orchid Cellmark
Orchid Cellmark is a leading provider of identity DNA testing services for the human identity and agriculture markets. In the human identity area, the company provides DNA testing services for forensic, family relationship and security applications. In the agriculture field, Orchid Cellmark provides DNA testing services for selective trait breeding. Orchid Cellmark’s strong market positions in these areas reflect the company’s accredited laboratories in the U.S. and U.K., its innovative genetic analysis technologies and expertise, and the world-renowned Cellmark brand that has been associated with exceptional quality, reliability and customer service for nearly two decades. More information on Orchid Cellmark can be found at www.orchid.com.

Contact:
Orchid Cellmark, Inc.
(609) 750-2200

Investors:
Mary Bashore
(609) 750-2324

Media:
Barbara Lindheim
Gendel Lindheim BioCom Partners
(212) 918-4650

All statements in this press release that are not historical are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding: Orchid Cellmark’s belief that the actions taken over the last year, along with a stronger balance sheet, have brought it closer to its goal of sustainable profitability and positive cash flow and Orchid Cellmark’s belief that it is in a good position to take advantage of strategic opportunities for growth. Such statements are subject to the risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of Orchid Cellmark’s products and services, dependence on government funding and collaborations, regulatory approvals, competition, intellectual property of others, patent protection, litigation, the timing of release of federal funds, the timing and amount of contracts put up for bid, Orchid Cellmark’s ability to timely hire qualified analysts, Orchid Cellmark’s ability to timely and successfully initiate operational efficiencies, lower overhead and other remedial measures and Orchid Cellmark’s ability to successfully offer its services directly to U.K. police forces. These risks and other additional factors affecting these statements and Orchid Cellmark’s business are discussed under the headings "Risks Related to Our Business" and "Risks Associated with Our Common Stock" in Orchid Cellmark’s Annual Report on Form 10-K, as amended, for the year ended December 31, 2006, as filed with the Securities and Exchange Commission, and in other filings made by Orchid Cellmark with the Securities and Exchange Commission from time to time. Orchid Cellmark expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Orchid Cellmark’s expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based, except as may be required by law.

Information contained in our press releases should be considered accurate only as of the date of the release. Information in any press release may be superseded by more recent information we have disclosed in later press releases, filings with the Securities and Exchange Commission or otherwise. Press releases may contain forward-looking statements based on the expectations of our management as of the date of the release. Actual results may materially differ based on several factors, including those described in the press release.